Journal of Current Glaucoma Practice

Register      Login

VOLUME 16 , ISSUE 3 ( September-December, 2022 ) > List of Articles


Glaucoma in Adults-diagnosis, Management, and Prediagnosis to End-stage, Categorizing Glaucoma's Stages: A Review

Poonam Joshi, Aayush Dangwal, Itika Guleria, Sunil Kothari, Pooja Singh, Jyoti M Kalra, Vikas Jakhmola

Keywords : Advanced glaucoma intervention study, Collaborative initial glaucoma treatment study, Closed angle glaucoma, Glaucoma, Glaucoma scrutility scale, Open-angle glaucoma

Citation Information : Joshi P, Dangwal A, Guleria I, Kothari S, Singh P, Kalra JM, Jakhmola V. Glaucoma in Adults-diagnosis, Management, and Prediagnosis to End-stage, Categorizing Glaucoma's Stages: A Review. J Curr Glaucoma Pract 2022; 16 (3):170-178.

DOI: 10.5005/jp-journals-10078-1388

License: CC BY-NC 4.0

Published Online: 23-01-2023

Copyright Statement:  Copyright © 2022; The Author(s).


Importance: Most frequent worldwide cause of permanent blindness is glaucoma. Early in the course of the disease, glaucoma affects many patients without any symptoms. In order to examine for indications of glaucoma and to ascertain whether systemic illnesses or drugs can raise a patient's risk of developing glaucoma, primary care practitioners should be aware of which patients to send to an eye care specialist. A review of the pathogenesis, risk factors, screening, disease monitoring, and treatment options for open-angle and narrow-angle glaucoma are included. Observations: The optic nerve and retinal nerve fiber layer (rNFL) are damaged in glaucoma, a chronic, progressive optic neuropathy that can result in a permanent loss of peripheral or central vision. The only risk factor that is known to be controllable is intraocular pressure (IOP). A family history of glaucoma, older age, and non-white race are additional significant risk factors. Numerous systemic diseases and drugs, such as corticosteroids, anticholinergics, certain antidepressants, and topiramate, can put people at risk of developing glaucoma. Open-angle and angle-closure glaucoma are the two main types of disease. Measurement of IOP, perimetry, and optical coherence tomography are diagnostic procedures to evaluate glaucoma and track the course of the condition. In order to treat glaucoma, IOP must be decreased. This is possible with a variety of glaucoma medication classes, laser surgery, and incisional surgery. Verdicts and relevance: By identifying systemic illnesses and drugs that raise a patient's chance of developing glaucoma and referring high-risk individuals for a thorough ophthalmologic examination, vision loss from glaucoma can be reduced. Clinicians should make sure that patients continue taking their glaucoma drugs as prescribed and should keep an eye out for any negative side effects from any medical or surgical procedures used to treat glaucoma.

PDF Share
  1. Schuster AK, Erb C, Hoffmann EM, et al. The diagnosis and treatment of glaucoma. Dtsch Arztebl Int 2020:117(13):225–234. DOI: 10.3238/arztebl.2020.0225
  2. Coleman AL, Brigatti L. The glaucomas. Minerva Med 2001;92(5):365–379. PMID: 11675580.
  3. Jonas JB, Aung T, Bourne RR. Glaucoma. Lancet 2017;390(10108):2183–2193. DOI: 10.1016/S0140-6736(17)31469-1
  4. Glick H, Brainsky A, McDonald RC, et al. The cost of glaucoma in the United States in 1988. Chibret Int J Ophthalmol 1994;10:6–12.
  5. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998;7(2):95–104. PMID: 9559495.
  6. Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Physician 2003;67(9):1937–1944. PMID: 12751655.
  7. Riordan-Eva P, Vaughan DG. Eye. In: Tierney LM Jr, McPhee SJ, Papadakis MA, editors. Current medical diagnosis and treatment. New York: Lange Medical Books/McGraw-Hill, 2001:185–216.
  8. Barnebey H. Screening for glaucoma. In: Fihn SD, De Witt DE, editor. Outpatient medicine Philadelphia: Saunders,1998:119–120.
  9. Advanced glaucoma intervention study: 2. Visual field test scoring and reliability. Ophthalmology 1994;101(8):1445–1455. DOI: 10.1016/S0161-6420(94)31171-7
  10. Katz J. Scoring systems for measuring progression of visual field loss in clinical trials of glaucoma treatment. Ophthalmology 1999;106(2):391–395. DOI: 10.1016/S0161-6420(99)90052-0
  11. Chen PP, Park RJ. Visual field progression in patients with initially unilateral visual field loss from chronic open-angle glaucoma. Ophthalmology 2000;107(9):1688–1692. DOI: 10.1016/s0161-6420(00)00229-3
  12. Musch DC, Lichter PR, Guire KE, et al. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 1999;106(4):653–662. DOI: 10.1016/s0161-6420(99)90147-1
  13. Mills RP, Drance SM. Esterman disability rating in severe glaucoma. Ophthalmology 1986;93(3):371–378. DOI: 10.1016/s0161-6420(86)33732-1
  14. Hodapp E, Parrish RK, Anderson DR. Clinical decisions in glaucoma. St. Louis: Mosby 1993:53.
  15. Katz J, Sommer A, Gaasterland DE, et al. Comparison of analytic algorithms for detecting glaucomatous visual field loss. Arch Ophthalmol 1991;109(12):1684–1689. DOI: 10.1001/archopht.1991.01080120068028
  16. Anderson DR. Automated Static Perimetry. St. Louis, Mosby, 1995.
  17. Alward WL. Medical management of glaucoma. N Engl J Med 1998;339(18):1298–1307. DOI: 10.1056/NEJM199810293391808
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.